Lung Cancer Clinical Trials in New Orleans, LA

29 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	Phase 3	National Cancer Institute (NCI)	<1 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer	Phase 2/3	SWOG Cancer Research Network	<1 mi
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy	Phase 3	Boehringer Ingelheim	<1 mi
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs	Phase 1/2	Krystal Biotech, Inc.	<1 mi
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	Phase 3	Eli Lilly and Company	<1 mi
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)	Phase 3	Nuvation Bio Inc.	<1 mi
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors	Phase 1	Olema Pharmaceuticals, Inc.	<1 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer	Phase 3	NRG Oncology	<1 mi
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier	—	Veracyte, Inc.	<1 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation	—	Guardant Health, Inc.	<1 mi
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase 1/2	Turning Point Therapeutics, Inc.	<1 mi
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.	Phase 4	AstraZeneca	<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	Phase 3	Children's Oncology Group	<1 mi
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors	Phase 1	Pfizer	<1 mi
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia	—	University of Rochester	<1 mi
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change	Phase 2	National Cancer Institute (NCI)	<1 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	Phase 3	National Cancer Institute (NCI)	<1 mi
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer	Phase 3	University of Texas Southwestern Medical Center	<1 mi
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans	N/A	Louisiana State University Health Sciences Center in New Orleans	<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	<1 mi
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors	Phase 1	Astellas Pharma Inc	5 mi
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor	Phase 3	OSE Immunotherapeutics	36 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	Phase 3	Summit Therapeutics	36 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	Phase 3	AstraZeneca	36 mi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Pfizer	36 mi
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7	Phase 2/3	Mirati Therapeutics Inc.	36 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	36 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.